Ability of different lopinavir genotypic inhibitory quotients to predict 48-week virological response in highly treatment-experienced HIV-infected patients receiving lopinavir/ritonavir

Journal of Medical Virology

Volumn 78, Issue 12, 2006, Pages 1537-1541

  Gianotti, Nicola ^a,c   Galli, Laura ^a   Danise, Anna ^a   Hasson, Hamid ^a   Boeri, Enzo ^b   Lazzarin, Adriano ^a   Castagna, Antonella ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b Diagnostica and Ricerca San Raffaele   (Italy)

^c SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

HIV genotype; HIV protease inhibitors; HIV protease inhibitors concentrations; HIV resistance; HIV treatment efficacy

Indexed keywords

LOPINAVIR PLUS RITONAVIR; PROTEINASE INHIBITOR; VIRUS RNA;

ARTICLE; CLINICAL ARTICLE; GENOTYPE; GENOTYPIC INHIBITORY QUOTIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MATHEMATICAL ANALYSIS; MULTIVARIATE ANALYSIS; TREATMENT RESPONSE; VIRUS LOAD; VIRUS MUTATION; VIRUS RESISTANCE;

ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; GENOTYPE; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PYRIMIDINONES; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; TREATMENT OUTCOME;

EID: 33750546218     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.20736     Document Type: Article

References (11)

1. Castagna A, Gianotti N, Galli L, Danise A, Hasson H, Boeri E, Hoetelmans R, Nauwelaers D, Lazzarin A. 2004. The NIQ of lopinavir is predictive of a 48-week virological response in highly treatment-experienced HIV-1-infected subjects treated with a lopinavir/ritonavir-containing regimen. Antivir Ther 9:537-543.
2. Hsu A, Isaacson J, Brun S, Bernstein B, Lam W, Bertz R, Foit C, Rynkiewicz K, Richards B, King M, Rode R, Kempf DJ, Granneman GR, Sun E. 2003. Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 47:350-359.
3. Isaacson J, Kempf D, Calvez V, Cohen-Codar I, Descamps D, Guillevic E, Bernstein B, Sun E, Chauvin J, Rode R. 2002. Quantitative estimate of the effect of individual baseline mutations in HIV protease on the virologic response to lopinavir/ritonavir therapy in heavily antiretroviral-experienced patients. Abstract 559-T. In Programme and Abstracts of the 9th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, February 24-28.
4. Johnson VA, Brun-Vezinet F, Clotet B, Conway B, Kuritzkes DR, Pillay D, Schapiro J, Telenti A, Richman D. 2005. Update of the drug resistance mutations in HIV-1: 2005. Top HIV Med 13:51-57.
5. Kempf DJ, Isaacson JD, King MS, Brun SC, Sylte J, Richards B, Bernstein B, Rode R, Sun E. 2002. Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir therapy. Antivir Ther 7:165-174.
6. Loutfy MR, Raboud JM, Walmsley SL, Saskin R, Montaner JS, Hogg RS, Thompson CA, Harrigan PR. 2004. Predictive value of HIV-1 protease genotype and virtual phenotype on the virological response to lopinavir/ritonavir-containing salvage regimens. Antivir Ther 9:595-602.
7. Marcelin AG, Lamotte C, Delaugerre C, Ktorza N, Ait Mohand H, R. Cacace R, Bonmarchand M, Wirden M, Simon A, Bossi P, Bricaire F, Costagliola D, Katlama C, Peytavin G, Calvez V, Genophar Study Group. 2003. Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients. Antimicrob Agents Chemother 47:594-600.
8. Marcelin AG, Dalban C, Peytavin G, Lamotte C, Agher R, Delaugerre C, Wirden M, Conan F, Dantin S, Katlama C, Costagliola D, Calvez V. 2004. Clinically relevant interpretation of genotype and relationship to plasma drug concentrations for resistance to saquinavir-ritonavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients. Antimicrob Agents Chemother 48:4687-4692.
9. Marcelin AG, Cohen-Codar I, King MS, Colson P, Guillevic E, Descamps D, Lamotte C, Schneider V, Ritter J, Segondy M, Peigue-Lafeuille H, Morand-Joubert L, Schmuck A, Ruffault A, Palmer P, Chaix ML, Mackiewicz V, Brodard V, Izopet J, Cottalorda J, Kohli E, Chauvin JP, Kempf DJ, Peytavin G, Calvez V. 2005. Virological and pharmacological parameters predicting the response to lopinavir-ritonavir in heavily protease inhibitor-experienced patients. Antimicrob Agents Chemother 49:1720-1726.
10. Norton M, Kempf D, Brun S, Omachi J, Cernohous P, King M. 2004. Genotypic algorithms specific to lopinavir/ritonavir outperform nonspecific lists of PI mutations in predicting virological response to lopinavir/ritonavir in Pi-experienced patients. Abstract 117. In Programme and Abstracts of the XIII International HIV Drug Resistance Workshop: Basic Principles and Clinical Implications, Tenerife, Canary Islands, Spain, June 8-10.
11. Parkin NT, Chappey C, Petropoulos CJ. 2003. Improving lopinavir genotype algorithm through phenotype correlations: Novel mutation patterns and amprenavir cross-resistance. AIDS 17:955-961.